Amichai Perlman
Overview
Explore the profile of Amichai Perlman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
437
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perlman A, Pickman Y, Dreyfuss M, Manes I, Bak P, Souroujon D, et al.
J Telemed Telecare
. 2024 Mar;
:1357633X241233788.
PMID: 38484299
Objective: To evaluate the clinical outcomes of a remote mental health program for managing anxiety and depression, primarily using asynchronous digital communication. Methods: This retrospective cohort study examined U.S. adults...
2.
Perlman A, Goldstein R, Choshen Cohen L, Hirsh-Raccah B, Hakimian D, Matok I, et al.
CNS Drugs
. 2021 Aug;
35(8):919.
PMID: 34342849
No abstract available.
3.
Israel S, Perlman A, Moran-Gilad J, Korem M
J Clin Microbiol
. 2021 Apr;
59(7):e0031121.
PMID: 33883184
Direct susceptibility testing from blood cultures has been reported to reduce the time interval between a positive blood culture to preliminary reporting of susceptibility and can underpin timely appropriate treatment...
4.
Perlman A, Goldstein R, Choshen Cohen L, Hirsh-Raccah B, Hakimian D, Matok I, et al.
CNS Drugs
. 2021 Feb;
35(3):305-316.
PMID: 33595834
Background: Stroke and thromboembolic events occurring among patients taking direct oral anticoagulants (DOACs) have been associated with low concentrations of DOACs. Enzyme-inducing antiseizure medications (EI-ASMs) are associated with enhanced cytochrome-P450-mediated...
5.
Perlman A, Vodonos Zilberg A, Bak P, Dreyfuss M, Leventer-Roberts M, Vurembrand Y, et al.
J Med Internet Res
. 2020 Sep;
22(10):e23197.
PMID: 32961527
Background: Patient-facing digital health tools have been promoted to help patients manage concerns related to COVID-19 and to enable remote care and self-care during the COVID-19 pandemic. It has also...
6.
Hirsch A, Wanounou M, Perlman A, Hirsh-Raccah B, Muszkat M
BMC Pharmacol Toxicol
. 2020 Jul;
21(1):47.
PMID: 32600424
Background: In acute intoxication, carbamazepine concentration above 40 mcg/ml is associated with a risk of severe neurological consequences, including depressed consciousness, respiratory depression, cardiac conduction disorders, seizures, and death. Carbamazepine...
7.
Gorelik E, Gorelik B, Masarwa R, Perlman A, Hirsh-Raccah B, Matok I
Int J Obes (Lond)
. 2020 Mar;
44(5):1021-1027.
PMID: 32152496
Aims: Over the past several decades, many antiobesity drugs have been withdrawn from the market due to unanticipated adverse events, often involving cardiotoxicity. This study aimed to evaluate the presence...
8.
Perlman A, Wanounou M, Goldstein R, Choshen Cohen L, Singer D, Muszkat M
CNS Drugs
. 2019 Nov;
33(12):1223-1228.
PMID: 31686406
Introduction: Factor Xa-inhibiting direct oral anticoagulants (FXa-DOACs) undergo hepatic metabolism via cytochrome P-450 (CYP450). Concomitant use of rifampicin, an inducer of these enzymes, with FXa-DOACs, has been shown to decrease...
9.
Masarwa R, Perlman A, Levine H, Matok I
Am J Epidemiol
. 2019 Oct;
189(1):6-7.
PMID: 31576399
No abstract available.
10.
Rotshild V, Perlman A, Matok I
Ann Pharmacother
. 2019 May;
53(10):1074.
PMID: 31137953
No abstract available.